Suggestions
Markus Enzelberger
Partner at Versant Ventures
Markus Enzelberger is a highly experienced executive and scientist in the biotechnology industry. He currently serves as a Board Member at SixPeaks Bio, a biotech company based in Basel, Switzerland.1
Professional Experience
Enzelberger is a Partner at Versant Ventures, a leading healthcare venture capital firm, where he has been working since July 2020. In this role, he plays a central part in launching new companies from Versant's Ridgeline Discovery Engine in Basel.2
Prior to joining Versant, Enzelberger had a long and distinguished career at MorphoSys AG, a German biotechnology company:
- Chief Scientific Officer (CSO) from November 2017 to March 2020
- Interim CSO from April 2017 to October 2017
- Senior Vice President from March 2002 to April 2017
- Vice President from March 2002 to January 2012
Board Positions
In addition to his role at SixPeaks Bio, Enzelberger holds several other board positions:
- Matterhorn Biosciences (since July 2022)
- Granite Bio (since December 2021)
- Vector BioPharma (since September 2020)
- Ridgeline Discovery (since April 2020)
- Cimeio Therapeutics (since December 2020)
- GNA Biosolutions GmbH (since September 2018)
- T-knife (since September 2020)
Education
Enzelberger holds a Ph.D. in Chemistry from the University of Stuttgart, which he completed between 1990 and 1999. He also conducted postdoctoral research in Applied Physics at the California Institute of Technology from 1999 to 2002.
Expertise
Enzelberger is recognized as an authority in the field of protein engineering and has deep domain knowledge of drug discovery and development, especially in the protein field.2 His expertise has been crucial in his roles at both MorphoSys and Versant Ventures, where he has been involved in the creation and development of innovative biotech companies and therapeutic candidates.3
